Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome

(2009) Jayshri A. Shah et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease

(2008) A. ANSARI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review

(2008) Javier P. Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Undue reliance on I 2 in assessing heterogeneity may mislead

(2008) Gerta Rücker et al.   BMC Medical Research Methodology

Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine

(2008) Ahmed F. Hawwa et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold

(2008) Sharon J. Gardiner et al.   Clinical Gastroenterology and Hepatology

Removing barriers to a clinical pharmacogenetics service

(2008) William Newman et al.   Personalized Medicine

Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study

(2008) Sheldon C Cooper et al.   PHARMACOGENOMICS

Methodological quality of pharmacogenetic studies: Issues of concern

(2008) Andrea L. Jorgensen et al.   STATISTICS IN MEDICINE